WAM
NKTR icon

World Asset Management’s Nektar Therapeutics NKTR Stock Holding History

World Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-649
Closed -$346K – 1189
2019
Q2 		$346K Sell
649
-63
-9% -$31.6K 0.02% 788
2019
Q1 		$359K Sell
712
-18
-2% -$10.7K 0.02% 770
2018
Q4 		$360K Sell
730
-27
-4% -$16.3K 0.02% 688
2018
Q3 		$692K Buy
757
+47
+7% +$40.1K 0.03% 584
2018
Q2 		$520K Buy
710
+101
+17% +$116K 0.03% 696
2018
Q1 		$970K Buy
609
+3
+0.5% +$3.87K 0.05% 479
2017
Q4 		$543K Sell
606
-79
-12% -$46.7K 0.02% 841
2017
Q3 		$247K Buy
685
+7
+1% +$2.19K 0.01% 1249
2017
Q2 		$199K Buy
678
+36
+6% +$10.4K 0.01% 1348
2017
Q1 		$226K Buy
+642
New +$144K 0.01% 1223
2013
Q3 		– Sell
-729
Closed -$126K – 1755
2013
Q2 		$126K Buy
+729
New +$112K ﹤0.01% 1662

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

World Asset Management's NKTR Position: Q3 2019 in Review

World Asset Management sold out of Nektar Therapeutics (NKTR) in Q3 2019, closing a stake of 649 shares — an estimated $346K sold.

World Asset Management first reported a position in NKTR in Q2 2013 and held it in 11 quarters. The position peaked at $970K in Q1 2018. 287 funds tracked by Wall St. Rank hold NKTR as of Q3 2019.

  • World Asset Management reported no remaining Nektar Therapeutics position as of Q3 2019 after selling out during the quarter.
  • World Asset Management sold 649 Nektar Therapeutics shares in Q3 2019, an estimated $346K.
  • World Asset Management first reported a position in Nektar Therapeutics in Q2 2013 and held it in 11 quarters.
  • World Asset Management's Nektar Therapeutics position peaked at $970K in Q1 2018.
  • 287 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2019.

Based on World Asset Management's 13F filing for Q3 2019, filed 22 Oct 2019.